Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283026 | 0.89 | GAA (0.30) | GAA | |
| SCHEMBL1553874 | 0.70 | ALDH1A1 (0.42) | GAAALDH1A1PPARGPPARDPPARA | |
| SCHEMBL12803940 | 0.69 | NOS3 (0.34) | ALDH1A1TSHRKMT2A | |
| SCHEMBL327402 | 0.68 | GAA (0.40) | GAAALDH1A1PPARGPPARDPPARA | |
| SCHEMBL9332613 | 0.65 | GAA (0.53) | GAASMN1; SMN2KMT2A | |
| SCHEMBL29115719 | 0.65 | PTPN1 (0.47) | GAAALDH1A1PPARGPPARDXDH | |
| SCHEMBL12802117 | 0.64 | GAA (0.44) | GAAALDH1A1SMN1; SMN2CYP3A4ALOX15 | |
| SCHEMBL5879482 | 0.64 | CYP3A4 (0.50) | GAAALDH1A1PPARGPPARDPPARA | |
| SCHEMBL16950585 | 0.62 | TACR1 (0.37) | GAAALDH1A1PPARGPPARDPPARA | |
| SCHEMBL8125707 | 0.62 | ALDH1A1 (0.36) | GAAALDH1A1PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137045-A1 | Pyridinium Cationic Lipids as Gene Transfer Agents | BALABAN ALEXANDRU T | 2009-05-28 | — | — | US | disclosed |
| US-7456197-B2 | Pyridinium cationic lipids as gene transfer agents | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2008-11-25 | — | — | US | disclosed |
| US-20050196863-A1 | Pyridinium cationic lipids as gene transfer agents | TEXAS A & M UNIVERSITY, THE | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050196863-A1 | Pyridinium cationic lipids as gene transfer agents | PTDSS2, PLIN5, PTDSS1 | GAA 3793/4885ALDH1A1 3086/4885PPARG 787/4885 |
| US-20090137045-A1 | Pyridinium Cationic Lipids as Gene Transfer Agents | PTDSS2, PLIN5, PTDSS1 | GAA 3793/4885ALDH1A1 3086/4885PPARG 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.